Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Asthma

Treatments: Drug: Fluticasone propionate/salmeterol combination OP MD; Drug: Fluticasone propionate/salmeterol combination ED MD

Study type: Observational

Funder types: Industry

Identifiers

NCT01332357

112606

Details and patient eligibility

About

The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department visit using a retrospective observational cohort study design.

Enrollment: 6,139 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with asthma as determined by ICD-9 codes and asthma drug use
• at least 12 years of age
• discharged from an initial Emergency Department visit within 12 months

Exclusion criteria

• Subjects with COPD or treatment for COPD

Trial design

6,139 participants in 2 patient groups

Fluticasone propionate/salmeterol combination ED MD

Description:

Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician

Treatment:

Drug: Fluticasone propionate/salmeterol combination ED MD

Fluticasone propionate/salmeterol combination OP MD

Description:

Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician

Treatment:

Drug: Fluticasone propionate/salmeterol combination OP MD